These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 18239330)

  • 21. Safety of olanzapine use in adolescents.
    Schulz C; Haight RJ
    Expert Opin Drug Saf; 2013 Sep; 12(5):777-82. PubMed ID: 23876012
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.
    McQuade RD; Stock E; Marcus R; Jody D; Gharbia NA; Vanveggel S; Archibald D; Carson WH
    J Clin Psychiatry; 2004; 65 Suppl 18():47-56. PubMed ID: 15600384
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine.
    Chen CH; Chiu CC; Huang MC; Wu TH; Liu HC; Lu ML
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 May; 32(4):925-31. PubMed ID: 18082302
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of atypical antipsychotics on weight and serum lipid levels.
    Meyer JM
    J Clin Psychiatry; 2001; 62 Suppl 27():27-34; discussion 40-1. PubMed ID: 11806486
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine.
    Chrzanowski WK; Marcus RN; Torbeyns A; Nyilas M; McQuade RD
    Psychopharmacology (Berl); 2006 Dec; 189(2):259-66. PubMed ID: 17058105
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naïve population.
    Perez-Iglesias R; Mata I; Pelayo-Teran JM; Amado JA; Garcia-Unzueta MT; Berja A; Martinez-Garcia O; Vazquez-Barquero JL; Crespo-Facorro B
    Schizophr Res; 2009 Feb; 107(2-3):115-21. PubMed ID: 18993033
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HTR2C polymorphisms, olanzapine-induced weight gain and antipsychotic-induced metabolic syndrome in schizophrenia patients: a meta-analysis.
    Ma X; Maimaitirexiati T; Zhang R; Gui X; Zhang W; Xu G; Hu G
    Int J Psychiatry Clin Pract; 2014 Oct; 18(4):229-42. PubMed ID: 25152019
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia.
    Hosojima H; Togo T; Odawara T; Hasegawa K; Miura S; Kato Y; Kanai A; Kase A; Uchikado H; Hirayasu Y
    J Psychopharmacol; 2006 Jan; 20(1):75-9. PubMed ID: 16204328
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential effects of olanzapine and clozapine on plasma levels of adipocytokines and total ghrelin.
    Lu ML; Wang TN; Lin TY; Shao WC; Chang SH; Chou JY; Ho YF; Liao YT; Chen VC
    Prog Neuropsychopharmacol Biol Psychiatry; 2015 Apr; 58():47-50. PubMed ID: 25496829
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
    István S; Agoston T; Tamás T; Zoltán J
    Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Profound hypertriglyceridemia and weight gain in the first week following initiation of olanzapine: a case report with implications for lipid monitoring guidelines.
    Kimmel RJ; Levy MR
    Psychosomatics; 2013; 54(4):392-4. PubMed ID: 23261075
    [No Abstract]   [Full Text] [Related]  

  • 32. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
    Simpson GM; Glick ID; Weiden PJ; Romano SJ; Siu CO
    Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Olanzapine Is Faster than Haloperidol in Inducing Metabolic Abnormalities in Schizophrenic and Bipolar Patients.
    Fabrazzo M; Monteleone P; Prisco V; Perris F; Catapano F; Tortorella A; Monteleone AM; Steardo L; Maj M
    Neuropsychobiology; 2015; 72(1):29-36. PubMed ID: 26337616
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine.
    Gunes A; Melkersson KI; Scordo MG; Dahl ML
    J Clin Psychopharmacol; 2009 Feb; 29(1):65-8. PubMed ID: 19142110
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Dyslipidemia and schizophrenia].
    Wetterling T; Schneider B; Weber B
    Psychiatr Prax; 2007 Jul; 34(5):223-9. PubMed ID: 17160750
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia.
    Ascher-Svanum H; Stensland M; Zhao Z; Kinon BJ
    BMC Psychiatry; 2005 Jan; 5():3. PubMed ID: 15649317
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The time-dependent change of insulin secretion in schizophrenic patients treated with olanzapine.
    Chiu CC; Chen CH; Chen BY; Yu SH; Lu ML
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Aug; 34(6):866-70. PubMed ID: 20394794
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Latent Toxoplasma gondii infection is associated with decreased serum triglyceride to high-density lipoprotein cholesterol ratio in male patients with schizophrenia.
    Sagud M; Vlatkovic S; Svob Strac D; Sviben M; Zivkovic M; Vilibic M; Vuksan-Cusa B; Mihaljevic-Peles A; Pivac N
    Compr Psychiatry; 2018 Apr; 82():115-120. PubMed ID: 29477703
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized, 13-week study assessing the efficacy and metabolic effects of paliperidone palmitate injection and olanzapine in first-episode schizophrenia patients.
    Huang M; Yu L; Pan F; Lu S; Hu S; Hu J; Chen J; Jin P; Qi H; Xu Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2018 Feb; 81():122-130. PubMed ID: 29097257
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial.
    Kryzhanovskaya L; Schulz SC; McDougle C; Frazier J; Dittmann R; Robertson-Plouch C; Bauer T; Xu W; Wang W; Carlson J; Tohen M
    J Am Acad Child Adolesc Psychiatry; 2009 Jan; 48(1):60-70. PubMed ID: 19057413
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.